logo

SCIENCE CHINA Life Sciences, Volume 60, Issue 2: 202-214(2017) https://doi.org/10.1007/s11427-016-0369-6

A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling

More info
  • ReceivedNov 30, 2016
  • AcceptedDec 26, 2016

Abstract

Tumor angiogenesis is characterized by abnormal vessel morphology, endowing tumor with highly hypoxia and unresponsive toward treatment. To date, mounting angiogenic factors have been discovered as therapeutic targets in antiangiogenic drug development. Among them, vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors exerts potent antiangiogenic activity in tumor therapy. Therefore, it may provide a valid strategy for cancer treatment through targeting the tumor angiogenesis via VEGFR2 pathway. In this study, we established a high-profile compounds library and certificated a novel compound named N-(N-pyrrolidylacetyl)-9-(4-bromobenzyl)-1,3,4,9-tetrahydro-β-carboline (YF-452), which remarkably inhibited the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity invitro. Rat thoracic aorta ring assay indicated that YF-452 significantly blocked the formation of microvascular exvivo. In addition, YF-452 inhibited angiogenesis in chick chorioallantoic membrane (CAM) and mouse corneal micropocket assays. Moreover, YF-452 remarkably suppressed tumor growth in xenografts mice model. Furthermore, investigation of molecular mechanism revealed that YF-452 inhibited VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. These results indicate that YF-452 inhibits angiogenesis and may be a potential antiangiogenic drug candidate for cancer therapy.


Funded by

Major State Basic Research Development Program of China(2015CB910400)

National Natural Science Foundation of China(81272463,81472788,81330049,81673304)

The Science and Technology Commission of Shanghai Municipality(15431902200)


Acknowledgment

This work was supported by Major State Basic Research Development Program of China (2015CB910400), National Natural Science Foundation of China (81272463, 81472788, 81330049, 81673304), and The Science and Technology Commission of Shanghai Municipality (15431902200).


Interest statement

The author(s) declare that they have no conflict of interest. All procedures performed in studies involving animals were in accordance with the ethical standards of the animal investigation committee of the Institute of Biomedical Sciences, East China Normal University.


Supplement

SUPPORTING INFORMATION

Figure S1 Migration inhibitory rate of selected nine compounds on HUVECs.

Figure S2 YF-452 concentration and time dependently suppressed HUVECs migration.

Figure S3 Vandetanib and sunitinib concentration dependently suppressed HUVECs invision.

Figure S4 Compared with vandetanib and sunitinib, YF-452 showed a better selectivity on HUVEC than PC-3 cells in MTS assay.

Figure S5 The synthesis route of small molecule compounds YF-452.

The supporting information is available online at life.scichina.com and www.springerlink.com. The supporting materials are published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains entirely with the authors.


References

[1] Abedi H., Zachary I.. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem, 1997, 272: 15442-15451 CrossRef Google Scholar

[2] Avraham H.K., Lee T.H., Koh Y., Kim T.A., Jiang S., Sussman M., Samarel A.M., Avraham S.. Vascular endothelial growth factor regulates focal adhesion assembly in human brain microvascular endothelial cells through activation of the focal adhesion kinase and related adhesion focal tyrosine kinase. J Biol Chem, 2003, 278: 36661-36668 CrossRef PubMed Google Scholar

[3] Berra E., Milanini J., Richard D.E., Le Gall M., Viñals F., Gothié E., Roux D., Pagès G., Pouysségur J.. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol, 2000, 60: 1171-1178 CrossRef Google Scholar

[4] Boehm T., Folkman J., Browder T., O’Reilly M.S.. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 1997, 390: 404-407 CrossRef PubMed ADS Google Scholar

[5] Capozzi M., VON Arx C., DE Divitiis C., Ottaiano A., Tatangelo F., Romano G.M., Tafuto S., Tafuto S.. Antiangiogenic therapy in pancreatic neuroendocrine tumors. Anticancer Res, 2016, 36: 5025-5030 CrossRef PubMed Google Scholar

[6] Carmeliet P., Jain R.K.. Molecular mechanisms and clinical applications of angiogenesis. Nature, 2011, 473: 298-307 CrossRef PubMed ADS Google Scholar

[7] Cho C.H., Lee C.S., Chang M., Jang I.H., Kim S.J., Hwang I., Ryu S.H., Lee C.O., Koh G.Y.. Localization of VEGFR-2 and PLD2 in endothelial caveolae is involved in VEGF-induced phosphorylation of MEK and ERK. Am J Physiol Heart Circ Physiol, 2004, 286: H1881-H1888 CrossRef PubMed Google Scholar

[8] Chung B.H., Cho Y.L., Kim J.D., Jo H.S., Won M.H., Lee H., Ha K.S., Kwon Y.G., Kim Y.M.. Promotion of direct angiogenesis in vitro and in vivo by Puerariae flos extract via activation of MEK/ERK-, PI3K/Akt/eNOS-, and Src/FAK-dependent pathways. Phytother Res, 2010, 24: 934-940 CrossRef PubMed Google Scholar

[9] Dai F., Chen Y., Song Y., Huang L., Zhai D., Dong Y., Lai L., Zhang T., Li D., Pang X., Liu M., Yi Z.. A natural small molecule harmine inhibits angiogenesis and suppresses tumour growth through activation of p53 in endothelial cells. PLoS ONE, 2012, 7: e52162 CrossRef PubMed ADS Google Scholar

[10] De Falco S.. Antiangiogenesis therapy: an update after the first decade. Korean J Intern Med, 2014, 29: 1-11 CrossRef PubMed Google Scholar

[11] Dong Y., Lu B., Zhang X., Zhang J., Lai L., Li D., Wu Y., Song Y., Luo J., Pang X., Yi Z., Liu M.. Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. Carcinogenesis, 2010, 31: 2097-2104 CrossRef PubMed Google Scholar

[12] Dong Y., Zhang T., Li J., Deng H., Song Y., Zhai D., Peng Y., Lu X., Liu M., Zhao Y., Yi Z.. Oridonin inhibits tumor growth and metastasis through anti-angiogenesis by blocking the notch signaling. PLoS ONE, 2014, 9: e113830 CrossRef PubMed ADS Google Scholar

[13] Eliceiri B.P., Puente X.S., Hood J.D., Stupack D.G., Schlaepfer D.D., Huang X.Z., Sheppard D., Cheresh D.A.. Src-mediated coupling of focal adhesion kinase to integrin αvβ5 in vascular endothelial growth factor signaling. J Cell Biol, 2002, 157: 149-160 CrossRef PubMed Google Scholar

[14] Folkman J.. Tumor angiogenesis: therapeutic implications. N Engl J Med, 1971, 285: 1182-1186 CrossRef PubMed Google Scholar

[15] Fontanella, C., Ongaro, E., Bolzonello, S., Guardascione, M., Fasola, G., and Aprile, G. (2014). Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med 2, 123. Google Scholar

[16] Goodwin A.M.. In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents. Microvasc Res, 2007, 74: 172-183 CrossRef PubMed Google Scholar

[17] Holmqvist K., Cross M.J., Rolny C., Hägerkvist R., Rahimi N., Matsumoto T., Claesson-Welsh L., Welsh M.. The adaptor protein Shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem, 2004, 279: 22267-22275 CrossRef PubMed Google Scholar

[18] Huang B.. Tumor microenvironment: a mechanical force link. Sci China Life Sci, 2015, 58: 202-204 CrossRef PubMed Google Scholar

[19] Jain R.K.. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol, 2013, 31: 2205-2218 CrossRef PubMed Google Scholar

[20] Jayson G.C., Kerbel R., Ellis L.M., Harris A.L.. Antiangiogenic therapy in oncology: current status and future directions. Lancet, 2016, 388: 518-529 CrossRef Google Scholar

[21] Jiang B.H., Liu L.Z.. AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets, 2008, 8: 19-26 CrossRef Google Scholar

[22] Lai L., Liu J., Zhai D., Lin Q., He L., Dong Y., Zhang J., Lu B., Chen Y., Yi Z., Liu M.. Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2. British J Pharmacol, 2012, 165: 1084-1096 CrossRef PubMed Google Scholar

[23] Liu F., Tan G., Li J., Dong X., Krissansen G.W., Sun X.. Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice. Cancer Sci, 2007, 98: 1381-1387 CrossRef PubMed Google Scholar

[24] Liu J., Agarwal S.. Mechanical signals activate vascular endothelial growth factor receptor-2 to upregulate endothelial cell proliferation during inflammation. J Immunol, 2010, 185: 1215-1221 CrossRef Google Scholar

[25] Medici D., Olsen B.R.. Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF. PLoS ONE, 2012, 7: e42913 CrossRef PubMed ADS Google Scholar

[26] Murphy D.A., Makonnen S., Lassoued W., Feldman M.D., Carter C., Lee W.M.F.. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol, 2006, 169: 1875-1885 CrossRef PubMed Google Scholar

[27] Nagy J.A., Dvorak H.F.. Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets. Clin Exp Metastasis, 2012, 29: 657-662 CrossRef PubMed Google Scholar

[28] Pagès G., Milanini J., Richard D.E., Berra E., GothiÉ E., Viñals F., PouyssÉGur J.. Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann New York Acad Sci, 2000, 902: 187-200 CrossRef ADS Google Scholar

[29] Pang X., Yi Z., Zhang X., Sung B., Qu W., Lian X., Aggarwal B.B., Liu M.. Acetyl-11-keto-β-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res, 2009, 69: 5893-5900 CrossRef PubMed Google Scholar

[30] Pentheroudakis G., Kotoula V., Kouvatseas G., Charalambous E., Dionysopoulos D., Zagouri F., Koutras A., Papazisis K., Pectasides D., Samantas E., Dimopoulos M.A., Papandreou C.N., Fountzilas G.. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer. Clin Breast Cancer, 2014, 14: 330-338 CrossRef PubMed Google Scholar

[31] Pober J.S., Sessa W.C.. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol, 2007, 7: 803-815 CrossRef PubMed Google Scholar

[32] Qi J.H., Claesson-Welsh L.. VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase. Exp Cell Res, 2001, 263: 173-182 CrossRef PubMed Google Scholar

[33] Saraswati S., Agrawal S.S.. Brucine, an indole alkaloid from Strychnos nux-vomica attenuates VEGF-induced angiogenesis via inhibiting VEGFR2 signaling pathway in vitro and in vivo. Cancer Lett, 2013, 332: 83-93 CrossRef PubMed Google Scholar

[34] Schlessinger J.. New roles for src kinases in control of cell survival and angiogenesis. Cell, 2000, 100: 293-296 CrossRef Google Scholar

[35] Schwartz S., George J., Ben-Shoshan J., Luboshits G., Avni I., Levkovitch-Verbin H., Ziv H., Rosner M., Barak A.. Drug modification of angiogenesis in a rat cornea model. Invest Ophthalmol Vis Sci, 2008, 49: 250 CrossRef PubMed Google Scholar

[36] Shen K., Ji L., Gong C., Ma Y., Yang L., Fan Y., Hou M., Wang Z.. Notoginsenoside Ft1 promotes angiogenesis via HIF-1α mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways. Biochem Pharmacol, 2012, 84: 784-792 CrossRef PubMed Google Scholar

[37] Sitohy B., Nagy J.A., Dvorak H.F.. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res, 2012, 72: 1909-1914 CrossRef PubMed Google Scholar

[38] Somanath P.R., Razorenova O.V., Chen J., Byzova T.V.. Akt1 in endothelial cell and angiogenesis. Cell Cycle, 2006, 5: 512-518 CrossRef PubMed Google Scholar

[39] Song Y., Dai F., Zhai D., Dong Y., Zhang J., Lu B., Luo J., Liu M., Yi Z.. Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways. Angiogenesis, 2012, 15: 421-432 CrossRef PubMed Google Scholar

[40] Takahashi T., Yamaguchi S., Chida K., Shibuya M.. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J, 2001, 20: 2768-2778 CrossRef Google Scholar

[41] Tsoi M., Laguëëlle M.N., Boyer A., Paquet M., Nadeau M.È., Boerboom D.. Anti-VEGFA therapy reduces tumor growth and extends survival in a murine model of ovarian granulosa cell tumor. Transl Oncol, 2013, 6: 226-IN1 CrossRef Google Scholar

[42] Villanueva M.T.. Angiogenesis: a sudden rush of blood to the tumour. Nat Rev Cancer, 2015, 15: 135-135 CrossRef PubMed Google Scholar

[43] Wedge, S.R., Ogilvie, D.J., Dukes, M., Kendrew, J., Chester, R., Jackson, J.A., Boffey, S.J., Valentine, P.J., Curwen, J.O., Musgrove, H.L., Graham, G.A., Hughes, G.D., Thomas, A.P., Stokes, E.S., Curry, B., Richmond, G.H., Wadsworth, P.F., Bigley, A.L., and Hennequin, L.F. (2002). ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62, 4645–4655. Google Scholar

[44] Willmott L.J., Monk B.J.. Cervical cancer therapy: current, future and anti-angiogensis targeted treatment. Expert Rev Anticancer Therapy, 2009, 9: 895-903 CrossRef PubMed Google Scholar

[45] Xu D., Wang T.L., Sun L.P., You Q.D.. Recent progress of small molecular VEGFR inhibitors as anticancer agents. Mini Rev Med Chem, 2011, 11: 18-31 CrossRef Google Scholar

[46] Yan X.C., Yang Z.Y., Chen Y., Li N., Wang L., Dou G.R., Liu Y., Duan J.L., Feng L., Deng S.M., Han H., Zhang P.. Endothelial cells-targeted soluble human Delta-like 4 suppresses both physiological and pathological ocular angiogenesis. Sci China Life Sci, 2015, 58: 425-431 CrossRef PubMed Google Scholar

[47] Yang J.H., Hu J., Wan L., Chen L.J.. Barbigerone inhibits tumor angiogenesis, growth and metastasis in melanoma. Asian Pac J Cancer Prev, 2014, 15: 167-174 CrossRef Google Scholar

[48] Zachary I., Gliki G.. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res, 2001, 49: 568-581 CrossRef Google Scholar

[49] Zhang S., Cao Z., Tian H., Shen G., Ma Y., Xie H., Liu Y., Zhao C., Deng S., Yang Y., Zheng R., Li W., Zhang N., Liu S., Wang W., Dai L., Shi S., Cheng L., Pan Y., Feng S., Zhao X., Deng H., Yang S., Wei Y.. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clin Cancer Res, 2011, 17: 4439-4450 CrossRef PubMed Google Scholar

[50] Zhang Y.M., Dai B.L., Zheng L., Zhan Y.Z., Zhang J., Smith W.W., Wang X.L., Chen Y.N., He L.C.. A novel angiogenesis inhibitor impairs lovo cell survival via targeting against human VEGFR and its signaling pathway of phosphorylation. Cell Death Dis, 2012, 3: e406 CrossRef PubMed Google Scholar

[51] Zhao X., Su Y., You J., Gong L., Zhang Z., Wang M., Zhao Z., Zhang Z., Li X., Wang C.. Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects. Oncotarget, 2016, 7: 62619-62626 CrossRef PubMed Google Scholar

[52] Zhu A.X., Finn R.S., Mulcahy M., Gurtler J., Sun W., Schwartz J.D., Dalal R.P., Joshi A., Hozak R.R., Xu Y., Ancukiewicz M., Jain R.K., Nugent F.W., Duda D.G., Stuart K.. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res, 2013, 19: 6614-6623 CrossRef PubMed Google Scholar

  • Figure 1

    (Color online) Inhibitory effect on HUVECs migration, invasion and tube formation and toxicity evaluation of YF-452 in vitro. A, Chemical structure of YF-452. B, YF-452 inhibited HUVECs migration in wound healing assay. The cells were pretreated with mitomycin C to inhibit proliferation before inducing migration. Confluent HUVEC monolayers were scratch wounded and the cells were treated with indicated concentrations of YF-452 (0, 2.5, 5, 10, 20 μmol L−1), then photographed at different times (6 or 12 h), and the migrated cells were quantified by manual counting. Technical replicates n=3. C, YF-452 inhibited HUVECs invasion in transwell assay. HUVECs were seeded in the top chamber and treated with different concentrations of YF-452. After 12 h, the cells that invaded through the membrane were stained and quantified. Technical replicates n=3. D, YF-452 inhibited capillary-like tube formation of HUVECs. After treated with indicated concentrations of YF-452 for 10 h, capillary-like structure in each group was quantified by IPP 6.0 software. The percentage of inhibition was expressed using control as 100%. Technical replicates n=3. E, HUVECs YF-452 treated for 12 h were assayed for apoptosis by flow cytometry using an annexin V-FITC/PI apoptosis detection kit. F, HUVECs were plated on 0.1% gelatin-coated 96 well plates and then treated with the indicated concentrations of YF-452. Cell viability at different time (6, 12, 24, 48 h) was determined by MTS assay. Technical replicates n=3. Error bars, SD. **, P<0.01; ***, P<0.001.

  • Figure 2

    YF-452 inhibits angiogenesis ex vivo and in vivo. A, Representative images (left panel) and the optical density (right panel) of microvessels sprouting from rat thoracic aorta rings in the absence or presence of YF-452. The microvessel density of the untreated group was considered as 100%. Technical replicates n=3. B, YF-452 inhibited the formation of new blood vessels branches in CAM assay. Arrows pointed the new microvessels. Statistics indicated the percentage of inhibition and expressed using untreated group as 100%. Technical replicates n=8. C, YF-452 inhibited VEGF-induced angiogenesis in the mouse corneal micropocket assay. Red arrows pointed the micropellets and yellow arrows pointed VEGF-induced neovasculature. The statistical results showed the clock number, new vessel length and vessel area in each group. Images of both CAM and mouse corneal micropocket assays were obtained with OLYMPUS stereomicroscope. Technical replicates n=8. Error bars, SD. **, P<0.01; ***, P<0.001.

  • Figure 3

    (Color online) Antitumor effect and toxicity evaluation of YF-452 in vivo. PC-3 tumor-bearing nude mice were treated as described with YF-452 at 20, 40 mg kg−1 or with vehicle. A, Compared with vehicle group, YF-452-treated groups showed significant inhibition of tumor growth. Technical replicates n=8. B, The treatment with YF-452 resulted in significant inhibition of tumor volume versus vehicle control. Technical replicates n=8. C, YF-452 did not cause obvious change of body weights. D, YF-452 did not cause obvious pathologic abnormalities in normal tissues. HE staining of paraffin-embedded sections of the hearts, livers, spleens, lungs and kidneys. Error bars, SD. **, P<0.01; ***, P<0.001.

  • Figure 4

    YF-452 inhibits tumor angiogenesis and induces necrosis as well as apoptosis in xenograft mouse model. A, YF-452 inhibited angiogenesis in tumor. B, CD31 staining was performed to indicate the blood vessels in tumor tissues. YF-452 apparently decreased CD31 fluorescent signal (green) in treated groups verse vehicle group. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). Graph depicting CD31 immunofluorescence signal strengths in tumor tissues. C, Effect of YF-452 on the structural changes of tumors. Histopathological changes were observed under OLYMPUS stereomicroscope. Statistics indicated the percentage of necrotic areas per field (asterisks showed the necrotic tissue). D, Apoptosis was measured by cleaved caspase-3 staining in tumor sections. The treatment with YF-452 resulted in remarkably increased apoptosis versus vehicle control. Arrows indicated cleaved caspase-3 positive apoptotic cells. Statistics were calculated by cleaved caspase-3 positive cells/the total number of cells per field. Three random tumors were selected in three groups. Error bars, SD. *, P<0.05; **, P<0.001; ***, P<0.001.

  • Figure 5

    YF-452 inhibits the phosphorylation of VEGFR2 and its downstream signaling mediators. A, YF-452 suppressed the phosphorylation of VEGFR2 induced by VEGF in HUVECs. YF-452 also suppressed VEGFR2-mediated protein kinase activation of FAK, Src and ERK. B, To rule out YF-452 affecting tumor cells directly, expression of VEGFR2 and p-VEGFR2 were detected in HUVECs and PC-3 cells. Compared with HUVECs, a significantly lower expression of VEGFR2 in PC-3 cells was not sufficient to activate the phosphorylation of VEGFR2 and various downstream signaling molecules responsible for cell proliferation. C, The sensitivity of COS-7 cells to YF-452 was significantly increased after overexpression of VEGFR2. Error bars, SD. ***, P<0.001.

Copyright 2019 Science China Press Co., Ltd. 《中国科学》杂志社有限责任公司 版权所有

京ICP备18024590号-1